These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 38197578)
1. Urinary oxypurinol is a useful tool to assess adherence to allopurinol in clinical practice. Hasikova L; Bartl J; Stiburkova B Rheumatology (Oxford); 2024 May; 63(6):e174-e176. PubMed ID: 38197578 [No Abstract] [Full Text] [Related]
2. Plasma oxypurinol as a measure of adherence in clinical trials. Stamp LK; Merriman T; Frampton C; Zhang M; Wallace M; Miner JN; Dalbeth N Ann Rheum Dis; 2018 Feb; 77(2):313-314. PubMed ID: 28057666 [No Abstract] [Full Text] [Related]
3. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy. Keith MP; Gilliland WR Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966 [TBL] [Abstract][Full Text] [Related]
4. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Stamp L; Gow P; Sharples K; Raill B Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066 [TBL] [Abstract][Full Text] [Related]
9. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941 [TBL] [Abstract][Full Text] [Related]
10. An audit of a therapeutic drug monitoring service for allopurinol therapy. Kannangara DR; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout. Kankam M; Hall J; Gillen M; Yang X; Shen Z; Lee C; Liu S; Miner JN; Walker S; Clauson V; Wilson D; Nguyen M J Clin Pharmacol; 2018 Sep; 58(9):1214-1222. PubMed ID: 29733447 [TBL] [Abstract][Full Text] [Related]
12. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Zandman-Goddard G; Amital H; Shamrayevsky N; Raz R; Shalev V; Chodick G Rheumatology (Oxford); 2013 Jun; 52(6):1126-31. PubMed ID: 23392592 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data. Lin LW; Teng GG; Lim AYN; Yoong JS; Zethraeus N; Wee HL Int J Rheum Dis; 2019 Apr; 22(4):545-554. PubMed ID: 30556300 [TBL] [Abstract][Full Text] [Related]
14. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol]. Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882 [TBL] [Abstract][Full Text] [Related]